

University of California, San Francisco
CURRICULUM VITAE

Name: Frederick L. Baehner, MD

Position: HS Assistant Clinical Professor
Pathology
School of Medicine

Assistant Clinical Professor of Pathology
Vice President, Pathology & Oncology Development

Address: Box 1785
1600 Divisadero St., MZ Bldg Room, R200
University of California, San Francisco
San Francisco, CA 94116
Voice: 415-885-7301

Fax: 415-353-7676
Email: rick.baehner@ucsf.edu

Web: <http://www.ucsf.edu/pathology/pathology>

EDUCATION

1985 - 1990	University of Kansas, Lawrence, KS	B.A. Philosophy	Honors
1992 - 1997	University of Kansas, Kansas City, KS	M.D.	
1995 - 1996	University of Kansas, Kansas City, KS	Post-Sophomore Fellowship	Pathology
1997 - 1998	University of California, San Francisco	Resident	Anatomic Pathology
1998 - 1999	University of California, San Francisco	Resident	Lab Medicine
1999 - 2000	University of California, San Francisco	Resident	Anatomic Pathology
2000 - 2001	University of California, San Francisco	Chief Resident	Anatomic Pathology
2000 - 2001	University of California, San Francisco	Surgical Pathology Fellow	Anatomic Pathology
2001 - 2002	University of California, San Francisco	Cytopathology Fellow	Anatomic Pathology

2002 - 2003 University of California, San Francisco Hematopathology Fellow Lab Medicine

LICENSES, CERTIFICATION

1998 Medical Licensure, California
 2003 Board Certification, Anatomic and Clinical Pathology
 2005 Board Certification, Cytology

PRINCIPAL POSITIONS HELD

2003 - 2003	University of California, San Francisco	Clinical Instructor	Anatomic Pathology
2003 - 2005	University of California, San Francisco	Asst. Prof. of Clin. Path	Anatomic Pathology
2005 - present	University of California, San Francisco	MSP Staff Physician	Anatomic Pathology

OTHER POSITIONS HELD CONCURRENTLY

2003 - 2015	Hellen Diller Cancer Center	Director, Immunohistochemistry Core Laboratory
2005 - present	Genomic Health, Inc	Chief Medical Officer

HONORS AND AWARDS

1987 Honors Program Member, University of Kansas, Lawrence,
 1988 Honors Program Member, University of Kansas, Lawrence,
 1989 Honors Program Member, University of Kansas, Lawrence,
 1990 Honors Program Member, University of Kansas, Lawrence,
 1987 Dean's List, University of Kansas, Lawrence
 1988 Dean's List, University of Kansas, Lawrence
 1989 Dean's List, University of Kansas, Lawrence
 1990 Dean's List, University of Kansas, Lawrence

- 1992 Second Prize, University of Kansas Medical Center, Student Research Forum,
- 1995 Post-Sophomore Fellowship in Pathology, University of Kansas Medical Center,
- 1996 Post-Sophomore Fellowship in Pathology, University of Kansas Medical Center,
- 1997 Student Teaching Award
- 1998 Student Teaching Award
- 1999 Student Teaching Award
- 2000 Student Teaching Award
- 2001 Student Teaching Award
- 1998 Nominated for Outstanding Lab Instructor for Medical Students
- 1999 Chief Resident, Anatomic Pathology, San Francisco General Hospital
- 2000 Nominated for Outstanding Lab Instructor for Medical Students
- 2000 Lecturer, Chicanos & Latinos for Health Education
- 2001 Lecturer, Chicanos & Latinos for Health Education
- 2000 Chief Resident, Anatomic Pathology, UCSF, Moffitt-Long Hospital
- 2001 Chief Resident, Anatomic Pathology, UCSF, Moffitt-Long Hospital
- 2001 Nominated for Outstanding Lab Instructor for Medical Students
- 2002 UCSF Medical Center Service Excellency Award
- 2003 Lecturer, Chicanos & Latinos for Health Education

KEYWORDS/AREAS OF INTEREST

Next generation sequencing, liquid biopsy, cytology, fine needle aspiration, breast carcinoma, molecular classifiers, prognostic, predictive.

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

- 1997 - present United States and Canadian Academy of Pathology
- 2006 - present College of American Pathology
- 2008 - present American Society of Clinical Oncology
- 2005 - present Association of Molecular Pathology

SERVICE TO PROFESSIONAL ORGANIZATIONS

- 2005 - 2015 Immunohistochemistry Core Laboratory, Center Cancer, UCSF
Director, I have directed this core laboratory for 12 months of the year for one hour per day for the past 10 years ending in 2015.
- 2005 - present Cytopathology Service, UCSF
Attending, I attend 12 months of the year, 2 weeks per month on this service, supervising 1-2 house staff and 1 fellow. I have been doing this for 10 years - current.
- 2005 - present Surgical Pathology Service, UCSF
Attending, I attend 12 months of the year, 1-2 days per month, on this service, supervising 1 house staff or 1 fellow. I have been doing this for 10 years - current.

SERVICE TO PROFESSIONAL PUBLICATIONS

- 2009 - present Cancer Cytology

2009 - present Archives of Pathology and Laboratory Medicine
 2010 - present Journal of Clinical Oncology
 2010 - present Journal of Cancer Research
 2010 - present Journal of Clinical Oncology
 2010 - present Breast Cancer Research
 2011 - present New England Journal of Medicine

INVITED PRESENTATIONS - INTERNATIONAL

2006	5th Sentinel Node Congress in Rome, Italy (platform presentation)	Presenter
2007	2nd International Symposium on Cancer Metastasis and the Lymphovascular System. San Francisco, CA	Moderator and Speaker
2008	6th Biennial International Sentinel Node Society Meeting, Sydney, Australia	
2008	Second Annual International Course of Applied Immunohistochemistry and Molecular Morphology, Santa Barbara, CA (lecture)	Lecturer
2008	Keystone Symposia: Biomarker Discovery, Validation and Applications, Tahoe, CA (lecture)	Lecturer
2008	World Cancer Congress 2008, Shanghai, China (lecture)	Lecturer
2009	3rd International Symposium on Cancer Metastasis and the Lymphovascular System. San Francisco, CA	Moderator and speaker
2009	VIII Meeting of Clinical Oncology, Madrid Spain (poster)	Poster
2010	International Association of Pathology, Brazil (talk)	Lecturer
2013	St. Gallen Breast Cancer Conference, St. Gallen, Switzerland (posters)	Poster
2014	9th European Breast Cancer Conference (EBCC), Glasgow, Scotland (posters)	Poster
2014	European Society for Medical Oncology, Madrid, Spain (posters, poster discussions)	Lecturer
2015	St. Gallen Breast Cancer Conference; Vienna, Austria (posters; award)	Poster
2015	European Cancer Congress; Vienna, Austria (oral, posters, poster discussions)	Poster
2016	European Society for Medical Oncology; Copenhagen, Denmark (posters, poster discussions)	Poster
2017	St. Gallen Breast Conference; Vienna, Austria (posters)	Poster

2017	European Society for Medical Oncology; Madrid, Spain (posters)	Poster
2018	11th European Breast Cancer Conference (EBCC-11), Barcelona, Spain (poster)	Poster
2018	International and French Oncology Days; Paris, France	Presenter

INVITED PRESENTATIONS - NATIONAL

2000	United States and Canadian Academy of Pathology; New Orleans, LA (poster)	Presenter
2003	United States and Canadian Academy of Pathology; Chicago, IL (poster)	Presenter
2003	25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (platform)	Lecturer
2004	United States and Canadian Academy of Pathology; Vancouver, CA (5 posters)	Presenter
2004	Genomic Health Breast Oncology Summit, College of American Pathology, Phoenix, AZ (presentation)	Presenter
2004	26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (platform)	Lecturer
2005	United States and Canadian Academy of Pathology; San Antonio, TX (poster)	Presenter
2005	Association of Society of Clinical Oncology, Orlando, FL (platform)	
2005	27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (platform)	
2006	United States and Canadian Academy of Pathology; Atlanta, GA (poster)	Presenter
2006	Association of Society of Clinical Oncology, Atlanta, GA (poster)	Presenter
2006	College of American Pathology, San Diego, CA (½ day course)	Course Director
2006	28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (platform presentation)	Presenter
2007	United States and Canadian Academy of Pathology; San Diego, CA (posters/platform)	Presenter
2007	Association of Society of Clinical Oncology, Chicago, IL (poster)	Presenter

2007	Association of Society of Clinical Oncology - Breast, San Francisco, CA (poster & platform)	Presenter
2007	College of American Pathology, Chicago, IL (½ day course)	Course Director
2007	International Melanoma Congress, New York City, NY (poster)	Presenter
2007	29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (platforms/posters)	Presenter
2008	United States and Canadian Academy of Pathology; Denver, CO (platform/posters)	Presenter
2008	Association of Society of Clinical Oncology, Chicago, IL (posters/platforms)	Presenter
2008	Association of Society of Clinical Oncology - Breast, Washington, DC (poster & platform)	Presenter
2008	30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (posters & platform)	Presenter
2009	United States and Canadian Academy of Pathology; Boston, MA (posters & platform)	Presenter
2009	Association of Society of Clinical Oncology, Orlando, FL (posters & platform)	Presenter
2009	American Society of Clinical Pathology, Current Issues and Problems in Breast Pathology, Santa Barbara, CA	Invited lecturer
2009	Association of Society of Clinical Oncology - Breast, San Francisco, CA (poster)	Presenter
2009	31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX (poster)	Presenter
2010	United States and Canadian Academy of Pathology; Washington, DC (posters; platform)	Presenter
2010	Association of Society of Clinical Oncology, Chicago, IL (posters & platform)	Presenter
2010	American College of Surgeons, Washington DC	Invited Lecturer
2010	American Society for Therapeutic Radiology and Oncology, San Diego, CA	Invited Lecturer
2010	Association of Society of Clinical Oncology - Breast, Washington DC (platform and poster)	Presenter
2010	32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX (poster)	Presenter

2011	United States and Canadian Academy of Pathology; San Antonio, TX (poster)	Presenter
2011	American Association of Cancer Research, San Diego, CA	Invited Lecturer
2011	Association of Society of Clinical Oncology - Breast, San Francisco (poster)	Presenter
2011	33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX (poster, platform)	Presenter
2012	Association of Society of Clinical Oncology, Chicago, IL (posters & platform)	Presenter
2012	Association of Society of Clinical Oncology - Breast, San Francisco (posters, platform)	Presenter
2012	34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (poster, platform)	Presenter
2013	Association of Society of Clinical Oncology, Chicago, IL (posters, poster discussion)	Presenter
2013	American Urologic Association, San Diego, CA (platform)	Presenter
2013	Association of Society of Clinical Oncology - Breast, San Francisco (posters)	Presenter
2013	36th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (posters)	Presenter
2014	Association of Society of Clinical Oncology, Chicago, IL (posters, poster discussion, platform)	Presenter
2014	American Society for Therapeutic Radiology and Oncology, San Francisco, CA (poster)	Presenter
2014	Association of Society of Clinical Oncology - Breast, San Francisco (posters)	Presenter
2014	37th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (posters, oral)	Presenter
2015	United States and Canadian Academy of Pathology; Boston, MA (posters, platform)	Presenter
2015	Society of Surgical Oncology; Houston, TX (platform)	Presenter
2015	Association of Society of Clinical Oncology, Chicago, IL (posters, poster discussion)	Presenter
2015	American Society for Therapeutic Radiology and Oncology, San Antonio, TX (orals)	Presenter
2015	38th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (oral, posters)	Presenter

2016	Association of Society of Clinical Oncology, Chicago (posters)	Presenter
2016	39th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (posters)	Presenter
2017	Association of Society of Clinical Oncology, Chicago (posters)	Presenter
2017	College of American Pathology, Washington, DC (poster)	Presenter
2017	40th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (posters)	Presenter
2018	41st Annual San Antonio Breast Cancer Symposium, San Antonio, TX (poster)	Presenter

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

2003	Grand Rounds, Genzyme Corporation, Santa Fe, NM (presentation)	Presenter
2004	Genomic Health Breast Oncology Summit, SF, CA (presentation)	Presenter
2004	Genomic Health Breast Oncology Summit, Phoenix, AZ (presentation)	Presenter
2005	Current Issues in Pathology, Stanford & UCSF, San Francisco, CA (presentation)	Presenter
2006	Philippine Association of Medical Technologists, South San Francisco, CA (presentation)	Presenter
2006	Melanoma Sentinel Lymph Node Working Group, San Diego, CA (presentation)	Presenter
2006	Colorado Society of Clinical Pathology, Beaver Creek, CO (presentation)	Presenter
2006	Genomic Health Breast Oncology Summit, Baltimore, MD (presentation)	Presenter
2007	Melanoma Sentinel Lymph Node Working Group, Washington DC (presentation)	Presenter
2007	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2008	Kaiser Oakland Tumor Board, Molecular Diagnostics Talk, Oakland, CA (presentation)	Presenter
2009	Current Issues in Pathology, Stanford & UCSF, San Francisco, CA (presentation)	Presenter

2008	UCSF Practical Diagnostic Update in Gynecologic & Breast Pathology, SF, CA (presentation)	Presenter
2008	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2008	Pathology Visions, San Diego, CA (presentation)	Presenter
2009	Prostate Cancer Research Retreat, UCSF (presentation)	Presenter
2009	University of North Carolina, Tumor Board Presentation, Raleigh, NC	
2009	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2010	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2011	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2012	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2013	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2014	Long Island Society of Surgical Pathology, Long Island, NY (presentation)	Presenter
2014	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2015	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2016	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2017	34th Annual Miami Breast Cancer Conference, Miami, FL (poster)	Presenter
2017	Colorado Society of Clinical Pathology, Vail, CO (presentation)	Presenter
2018	35th Annual Miami Breast Cancer Conference, Miami, FL (poster)	Presenter
2018	UCSF Radiation Oncology Meeting, San Francisco, CA (oral)	Presenter

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

2000	United States and Canadian Academy of Pathology; New Orleans, LA
2003	United States and Canadian Academy of Pathology; Chicago, IL

2004 United States and Canadian Academy of Pathology; Vancouver, Canada

2004 College of American Pathology, Phoenix, AZ

2004 Association for Molecular Pathology, Los Angeles, CA

2004 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX

2005 United States and Canadian Academy of Pathology; San Antonio, TX

2005 American Society of Clinical Oncology, Orlando, FL

2005 Current Issues in Pathology, Stanford & UCSF, San Francisco, CA

2005 Association for Molecular Pathology, Scottsdale, AZ

2005 College of American Pathology, Phoenix, AZ

2005 American Society Clinical Pathology, Seattle, WA

2005 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX

2006 United States and Canadian Academy of Pathology; San Antonio, TX

2006 American Association of Cancer Research, Washington DC

2006 American Society of Clinical Oncology, Atlanta, GA

2006 College of American Pathology, San Diego, CA

2006 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX

2007 Society of Surgical Oncology, Washington DC

2007 United States and Canadian Academy of Pathology; San Diego, CA

2007 American Society of Clinical Oncology, Chicago, IL

2007 American Society of Clinical Oncology- Breast, San Francisco, CA

2007 College of American Pathology, Chicago, IL

2007 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX

2008 Second Annual International Course of Applied Immunohistochemistry and Molecular Morphology, Santa Barbara, CA

2008 Keystone Symposia: Biomarker Discovery, Validation & Applications, Tahoe, CA

2008 United States and Canadian Academy of Pathology; Denver, CO

2008 American Society of Clinical Oncology, Chicago, IL

2008 Futurescape of Pathology, Chicago, IL

2008 American Society of Clinical Oncology - Breast, Washington, DC

2008 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX

2009 United States and Canadian Academy of Pathology; Boston, MA

2009 American Society of Clinical Oncology, Orlando, FL
2009 DCIS Consensus Conference, Bethesda, MD
2009 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2010 United States and Canadian Academy of Pathology; Washington DC
2010 American Society of Clinical Oncology, Chicago, IL
2010 American Society of Clinical Oncology - Breast, Washington, DC
2010 American Society for Therapeutic Radiology and Oncology, San Diego, CA
2010 American College of Surgeons, Washington DC
2010 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2011 United States and Canadian Academy of Pathology; San Antonio, TX
2011 Miami Breast Symposium, Miami, FL
2011 American Association of Cancer Research, San Diego, CA
2011 American Society of Clinical Oncology, Chicago, IL
2011 American Society of Clinical Oncology - Breast, San Francisco, CA
2011 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2012 American Society of Clinical Oncology - GI, San Francisco, CA
2012 American Society of Clinical Oncology, Chicago, IL
2012 American Society of Clinical Oncology- Breast, San Francisco, CA
2012 European Society for Medical Oncology, Vienna, Austria, EU
2012 35th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2013 St. Gallen Breast Cancer Conference, St. Gallen, Switzerland
2013 Miami Breast Conference, Miami, FL
2013 American Society of Clinical Oncology, Chicago, IL
2013 American Urologic Association, San Diego, CA
2013 American Society of Clinical Oncology- Breast, San Francisco
2013 St. Gallen Breast Cancer Conference, St. Gallen, Switzerland
2013 36th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2014 Miami Breast Conference, Miami, FL
2014 9th European Breast Cancer Conference (EBCC), Glasgow, Scotland
2014 American Society of Clinical Oncology, Chicago, IL
2014 American Society of Clinical Oncology- Breast, San Francisco
2014 European Society for Medical Oncology, Madrid, Spain

2014 American Society for Therapeutic Radiology and Oncology, San Francisco, CA
2014 37th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2015 United States and Canadian Academy of Pathology; Boston, MA
2015 St. Gallen Breast Cancer Conference; Vienna, Austria
2015 American Society of Clinical Oncology, Chicago, IL
2015 European Cancer Congress; Vienna, Austria
2015 American Society for Therapeutic Radiology and Oncology, San Francisco, CA
2015 38th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2016 American Society of Clinical Oncology, Chicago, IL
2016 European Society for Medical Oncology; Copenhagen, Denmark
2016 39th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2017 American Association of Cancer Research, Washington DC
2017 American Society of Clinical Oncology, Chicago, IL
2017 European Society for Medical Oncology; Madrid, Spain
2017 40th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
2018 35th Annual Miami Breast Cancer Conference, Miami, FL
2018 11th European Breast Cancer Conference (EBCC-11), Barcelona, Spain
2018 American Association of Cancer Research, Chicago, IL
2018 American Society of Clinical Oncology, Chicago, IL
2018 30th European Congress of Pathology, Bilbao, Spain
2018 European Society for Medical Oncology; Munich, Germany
2018 41st Annual San Antonio Breast Conference Symposium, San Antonio, TX
2019 St. Gallen International Breast Cancer Conference, Vienna, Austria
2019 American Society of Clinical Oncology, Chicago, IL

GOVERNMENT AND OTHER PROFESSIONAL SERVICE

2000 - present Medical Advisory Board, Genomic Health Inc, Redwood City, CA
2006 - present Ad Hoc Immunohistochemistry Board to Develop Standards of Practice and submit guidelines to the Pathology Community; funded by Dako, Carpinteria, CA
2008 - 2008 Advisor, Office of Biorepositories and Biospecimen Research; NCI

- 2008 - 2008 International Forum for Standardization of Pathology Practices
- 2009 - 2010 Technology Assessment Committee, College of American Pathologists
- 2010 - 2011 Immunohistochemistry Committee, College of American Pathologists
- 2010 - present House of Delegates, College of American Pathologists

UNIVERSITY AND PUBLIC SERVICE

UNIVERSITY SERVICE

UC SYSTEM AND MULTI-CAMPUS SERVICE

- 2003 - 2005 UC Academic Senate
- 2003 - 2018 Helen Diller Mt. Zion Breast Tumor Board Presenting Pathologist

SCHOOL OF DENTISTRY

- 2002 - 2003 Pathology I and II, 1 didactic lab/week for yearlong course
- 2003 - 2004 Pathology I and II, 1 didactic lab/week for yearlong course
- 2004 - 2005 Pathology I and II, 1 didactic lab/week for yearlong course
- 2005 - 2006 Pathology I and II, 1 didactic lab/week for yearlong course
- 2006 - 2007 Pathology I and II, 1 didactic lab/week for yearlong course

TEACHING AND MENTORING

TEACHING SUMMARY

I currently am teaching/mentoring Cytopathology Fellows in the UCSF/Mt. Zion Cytopathology Clinic.

FORMAL TEACHING

	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	1997 - 2005	The Essential Core	Discussion Group Leader; 5 one hour sessions		20
	2004 - 2005	The Essential Core	Discussion Group Leader; 5 one hour sessions		20
	2005 - 2006	The Essential Core	Discussion Group Leader; 5 one hour sessions		20
	2006 - 2007	The Essential Core	Discussion Group Leader; 5 one hour sessions		20

	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2002 - 2003	Formal class or course teaching hours Pathology	20 hours	Medicine	
	2002 - 2003	Formal class or course teaching hours Pathology	16 hours	Dentistry	
	2002 - 2003	Formal class Hematopathology Didactics	20 hours	Medicine	
	2002 - 2003	Formal class Pathology Review Session	2 hours	Medicine	

INFORMAL TEACHING

- 2003 - 2004 500 hours of resident teaching (including preparation). Approximately 250 hours of surgical pathology sign-out time working with residents and approximately 250 hours of cytopathology sign-out and clinical time (in the fine-needle aspiration clinic, the ultrasound clinics, & the CT guided clinics).
- 2003 - 2004 520 total hours of teaching Pathology Laboratory for the Medical School, the Surgical Pathology and Cytopathology Residents and Fellows.
- 2004 - 2005 600 hours of resident teaching (including preparation). Approximately 250 hours of surgical pathology sign-out time working with residents and approximately 350 hours of cytopathology sign-out and clinical time (in the fine-needle aspiration clinic, the ultrasound clinics, & the CT guided clinics).
- 2004 - 2005 620 total hours of teaching Pathology Laboratory for the Medical School, the Surgical Pathology and Cytopathology Residents and Fellows.
- 2004 - 2006 120 total hours of teaching Pathology Laboratory for the Medical School, the Surgical Pathology and Cytopathology Residents and Fellows.
- 2005 - 2006 100 hours of resident teaching (including preparation). Approximately 50 hours of surgical pathology sign-out time working with residents and approximately 50 hours of cytopathology sign-out and clinical time (in the fine-needle aspiration clinic, the ultrasound clinics, & the CT guided clinics).
- 2006 - 2007 100 hours of resident teaching (including preparation). Approximately 50 hours of surgical pathology sign-out time working with residents and approximately 50 hours of cytopathology sign-out and clinical time (in the fine-needle aspiration clinic, the ultrasound clinics, & the CT guided clinics).
- 2007 - 2008 500 total hours of teaching Pathology Laboratory for the Medical School, the Surgical Pathology and Cytopathology Residents and Fellows.

2007 - 2008 100 hours of resident teaching (including preparation). Approximately 50 hours of surgical pathology sign-out time working with residents and approximately 50 hours of cytopathology sign-out and clinical time (in the fine-needle aspiration clinic, the ultrasound clinics, & the CT guided clinics).

2008 - 2009 100 hours of resident teaching (including preparation). Approximately 50 hours of surgical pathology sign-out time working with residents and approximately 50 hours of cytopathology sign-out and clinical time (in the fine-needle aspiration clinic, the ultrasound clinics, & the CT guided clinics).

POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2003 - 2004	Phil Holsten, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Staff at California Pacific Medical Center
2003 - 2004	Dawn Darbonne, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Private Practice
2004 - 2005	Robert Haas, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Private Practice
2004 - 2005	Eric Schwartz, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Staff at Stanford Medical Center
2005 - 2006	Kristin Jensen, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Staff at Stanford Medical Center
2005 - 2006	Matthew Greenberg, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Private Practice
2006 - 2007	Ian Jaffe, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Private Practice
2006 - 2007	Judy Pang, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Return To Residency

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2007 - 2008	Rebecca Swain, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Private Practice
2007 - 2008	Meika VanZante, MD	Cytology Fellow	Co-Mentor/Clinical Mentor	Clinical Supervisor	Staff at UCSF

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS - PAST

- | | | |
|--|-------------------------|---|
| 1. P30 CA82103-07
(FY06, direct)
Cancer Center Support Grant (NIH/NCI Core)
Cancer Center Support Grant
Running the immunohistochemistry core laboratory | 20 % effort
8/5/1999 | McCormick (PI)
5/31/2015
\$ 4,732,522 total |
|--|-------------------------|---|

- | | | |
|--------------------------------|-------------------------|---------------------------|
| 2. NIH R01

NIH/NCI Core | 20 % effort
1/1/2005 | Esserman (PI)
1/1/2013 |
|--------------------------------|-------------------------|---------------------------|

This grant is to examine with immunohistochemical stains from patient with breast cancer, to ascertain whether there are difference in macrophage activational status that correlate with the standard prognostic indicators in breast carcinoma.

- | | | |
|---|-----------|--|
| 3. W81XWH-07-1-0663

U.S. Army Medical Research and Material Command (USAMRMC) "Early detection of metastasis-prone breast cancers" | 9/17/2007 | Gray (PI)
9/16/2012
\$ 7,731,563 total |
|---|-----------|--|

The goal of this project is to develop imaging strategies that will detect metastasis prone cancer precursor lesions before they have matured, invaded and metastasized. Using expression arrays, RT-PCR, IHC and other molecular histopathology procedures we hope to discover and be able to detect in-vivo precursors that will reveal the true extent of pre-malignancies/malignancies and guide more complete surgical resections.

PEER REVIEWED PUBLICATIONS

1. Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test. Boolbol SK, Harshan M, Chadha M, Kirstein L, Cohen JM, Klein P, Anderson J, Davison D, Jakubowski DM, Baehner FL, Malamud S. Breast Cancer Res Treat. 2019 Jul 13. doi: 10.1007/s10549-019-05346-1.

2. Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. Dixon JM, Cameron DA, Arthur LM, Axelrod DM, Renshaw L, Thomas JS, Turnbull A, Young O, Loman CA, Jakubowski D, Baehner FL, Singh B. *Adv Ther*. 2019 Apr;36(4):828-841. Epub 2019 Mar 11.
3. The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, Frederick L. Baehner, Pierre Fumoleau, Magali Lacroix-Triki, Joseph M. Anderson, Carl Yoshizawa, Diana B. Cherbavaz, Steven Shak, Lise Roca, Christine Sagan, Jérôme Lemonnier, Anne-Laure Martin and Henri Roché. *BMC Cancer* 2018 18:526. Published on: 4 May 2018.
4. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Sestak I, Buus R, Cuzick J, Dubsy P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M. *JAMA Oncol*. 2018 Feb 15. doi: 10.1001/jamaoncol.2017.5524.
5. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ. *Breast Cancer Res Treat*. 2018 Jan 31. doi: 10.1007/s10549-018-4693-2.
6. Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. *J Natl Cancer Inst*. 2017 Jan 25;109(4).
7. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Ruck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Roberston SJ, Slodkowska E, Fong C, Anderson JM, Janshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L. Multigene Expression Assay and Benefit of Radiotherapy after Breast Conservation in DCIS. *J Natl Cancer Inst* 2017 April 109(4):1-8
8. Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. *J Natl Cancer Inst*. 2017 Jan 25;109(4).
9. Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. *NPJ Breast Cancer*. 2016 Jun 8;2:16017
10. Perez EA, Ballman KV, Mashadi-Hosseini A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. *J Natl Cancer Inst*. 2016 Feb 1;109(2):1-8.

11. Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. *Breast Cancer Res Treat.* 2017 Jan;161(1):17-28.
12. Baehner FL. The analytical validation of the Oncotype DX Recurrence Score assay. *Ecancermedalscience.* 2016 Sep 26;10:675.
13. Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ. The novel application of genomic profile assays to shorten inactive status for potential kidney transplant recipients with breast cancer. *Am J Transplant.* 2017 Jan;17(1):292-295.
14. Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J. Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. *Breast Cancer Res Treat.* 2016 Aug;159(1):71-8.
15. Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. *J Clin Oncol.* 2016 Jul 10;34(20):2350-8.
16. Alvarado MD, Prasad C, Rothney M, Cherbavaz DB, Sing AP, Baehner FL, Svedman C, Markopoulos CJ. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. *Adv Ther.* 2015 Dec;32(12):1237-47.
17. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. *JAMA Oncol.* 2016 Jan;2(1):56-64.
18. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. *Breast Cancer Res.* 2015 Oct 1;17(1):133.
19. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. 12. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. *J Clin Oncol.* 2015 Nov 20;33(33):3938-44.
20. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Robertson SJ, Slodkowska E, Fong C, Anderson JM, Jamshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. *Breast Cancer Res Treat.* 2015 Jul;152(2):389-98.
21. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. Harmonization of the evaluation of tumor infiltrating

- lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. *Ann Oncol*. 2015 Aug;26(2):259-271.
22. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. *Eur Urol*. 2014 Sep;66(3):550-60.
 23. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, Van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. *PLoS One*. 2013 Oct 29;8(10):e79114.
 24. Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR, Palacios J, Rakha E, Richardson AL, Schmitt FC, Tan PH, Tse GM, Vincent-Salomon A, Ellis IO, Badve S, Reis-Filho JS. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. *Am J Surg Pathol*. 2013 Jul;37(7):e1-11.
 25. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *J Natl Cancer Inst*. 2013 May 15;105(10):701-10.
 26. Nejadnik H, Henning TD, Do T, Sutton EJ, Baehner F, Horvai A, Sennino B, McDonald D, Meier R, Misselwitz B, Link TM, Daldrup-Link HE. MR imaging features of gadofluorine-labeled matrix-associated stem cell implants in cartilage defects. *PLoS One*. 2012;7(12):e49971.
 27. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. *Breast Cancer Res Treat*. 2012 Oct;135(3):913-22.
 28. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ. Elevated Levels of Proliferating and Recently Migrated Tumor-associated Macrophages Confer Increased Aggressiveness and Worse Outcomes in Breast Cancer. *Ann Surg Oncol*. 2012 Nov;19(12):3979-86.
 29. Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. *Breast Cancer Res Treat*. 2012 Jul;134(2):683-92.
 30. Baehner FL, Yoshizawa C, Shak S. Accurate assessment of human epidermal growth factor receptor 2. *J Clin Oncol*. 2012 May 10;30(14):1727-8; author reply 1728-9.
 31. Chang H, Fontenay GV, Han J, Cong G, Baehner FL, Gray JW, Spellman PT, Parvin B. Morphometric analysis of TCGA glioblastoma multiforme. *BMC Bioinformatics*. 2011 Dec 20;12:484.

32. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, Watson D, Shak S, Kerr DJ. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. *J Clin Oncol*. 2011 Dec 10;29(35):4611-9.
33. Baehner FL, Li R, Jenkins T, Hwang J, Kashani-Sabet M, Allen RE, Leong SP. The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival. *Ann Surg Oncol*. 2012 Mar;19(3):1034-42.
34. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S. Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer. *J Clin Oncol*. 2011 Nov 1;29(31):4160-7.
35. Sparano JA, Goldstein L, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman L, Martino S, Davidson NE, Kenny PA, Sledge GW Jr, Gray R, Sparano JA. Relationship Between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple Negative Breast Cancer. *Clin Cancer Res*. 2011 Nov 15;17(22):7194-203.
36. Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. *Breast Cancer Res Treat*. 2011 Nov;130(2):635-44.
37. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. *Breast Cancer Res Treat*. 2011 Sep;129(2):607-16.
38. Liu ML, Jeong J, Ambannavar R, Millward C, Baehner F, Sangli C, Dutta D, Pho M, Nguyen A, Cronin MT. RT-PCR gene expression profiling of RNA from paraffin-embedded tissues prepared using a range of different fixatives and conditions. *Methods Mol Biol*. 2011;724:205-37.
39. Baehner FL, Lee M, Demeure MJ, Bussey KJ, Kiefer JA, Barrett MT. Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. *J Surg Oncol*. 2011 May 1;103(6):563-73.
40. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. *Mod Pathol*. 2011 Feb;24(2):157-67.
41. Sutton EJ, Henning TD, Boddington S, Demos S, Krug C, Meier R, Kornak J, Zhao S, Baehner R, Sharifi S, Daldrup-Link H. In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label. *Mol Imaging*. 2010 Oct;9(5):278-90.
42. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III

Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin. *J Clin Oncol.* 2010 Sep 1;28(25):3937-44.

43. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. *Breast Cancer Res Treat.* 2011 Aug;128(3):703-11.
44. Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC, Gown AM, Habel LA. Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories. *J Clin Oncol.* 2010 Oct 1;28(28):4300-6.
45. Drury S, Salter J, Baehner FL, Shak S, Dowsett M. Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study. *J Clin Pathol.* 2010 Jun;63(6):513-7.
46. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. *Breast Cancer Res Treat.* 2010 Jan;119(1):137-44.
47. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. *J Clin Oncol.* 2010 Apr 10;28(11):1829-34.
48. Han J, Chang H, Giricz O, Lee GY, Baehner FL, Gray JW, Bissell MJ, Kenny PA, Parvin B. Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. *PLoS Comput Biol.* 2010 Feb 26;6(2):e1000684.
49. Sutton EJ, Boddington SE, Nedopil AJ, Henning TD, Demos SG, Baehner R, Sennino B, Lu Y, Daldrup-Link HE. An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis. *Opt Express.* 2009 Dec 21;17(26):24403-13.
50. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. *Clin Cancer Res.* 2009 Dec 15;15(24):7693-7700.
51. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol.* 2010 Jan;11(1):55-65.
52. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. *J Pathol.* 2010 Jan;220(2):263-80.

53. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW. A multimarker prognostic assay for primary cutaneous melanoma. *Clin Cancer Res*. 2009 Nov 15;15(22):6987-92.
54. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The Transmembrane src Substrate Trask Is an Epithelial Protein that Signals during Anchorage Deprivation. *Am J Pathol*. 2009 May;174(5):1756-65.
55. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. *Clin Cancer Res*. 2009 Apr 1;15(7):2311-22.
56. Yaziji H, Taylor CR, Goldstein NS, Dabbs, DJ; Baehner FL, Hammond E. Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry. *Appl Immunohistochem Mol Morphol*. 2008 Dec;16(6):513-20.
57. Goldstein LJ, Gray R, Childs BH, Watson D, Rowley S, Shak S, Badve S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Sparano JA. Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer Compared with Adjuvant, an Integrator of Clinicopathologic and Treatment Information. *J Clin Oncol*. 2008 Sep 1;26(25):4063-71.
58. Badve SS, Baehner FL, Gray RL, Childs BH, Maddala T, Liu ML, Rowley SL, Shak S, Perez ED, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. *J Clin Oncol*. 2008 May 20;26(15):2473-81.
59. Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. *Breast Cancer Res Treat*. 2008 Mar;108(2):233-40.
60. Saborowski O, Simon GH, Raatschen HJ, Wendland MF, Fu Y, Henning T, Baehner R, Corot C, Chen MH, Daldrup-Link HE. MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent. *Contrast Media Mol Imaging*. 2007 Mar;2(2):72-81.
61. Kim JY, Harvard C, You L, Xu Z, Kuchenbecker K, Baehner R, Jablons D. Stathmin is overexpressed in malignant mesothelioma. *Anticancer Res*. 2007 Jan-Feb;27(1A):39-44.
62. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell*. 2006 Dec;10(6):515-27.
63. Mina L, Soule SE, Badve S, Baehner FL, Baker J, Cronin M, Watson D, Liu ML, Sledge GW Jr, Shak S, Miller KD. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. *Breast Cancer Res Treat*. 2007 Jun;103(2):197-208.

64. Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. *J Clin Oncol.* 2006 Oct 1;24(28):4565-9.
65. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. *Cancer Res.* 2006 Sep 1;66(17):8707-14.
66. Paik S, Tang T, Shak S, Kim C, Baker J, Kim W, Cronin W, Baehner FL, Watson D, Bryant J, Costantino J, Geyer C, Wickerham DL, Wolmark N. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. *J Clin Oncol.* 2006 Aug 10;24(23):3726-34.
67. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner FL, Park CJ, Bissell MJ. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. *Cancer Res.* 2006 Feb 1;66(3):1526-35.
68. Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, LaPosa RR, Baehner FL, Sagebiel RW, Cleaver JE, Haqq C, Debs RJ, Blackburn EH, Kashani-Sabet M. Genes and pathways downstream of telomerase in the metastatic progression of melanoma. *Proc Natl Acad Sci U S A.* 2006 Jul 25;103(30):11306-11.
69. Park C, Zhang H, Pallavicini M, Gray JW, Baehner FL, Park CJ, Bissell M. Disrupting beta-1 integrin signaling inhibits growth, induces apoptosis, and effectively distinguishes malignant from normal phenotypes in 3D cultures and in vivo. *Cancer Research*, 2006 Feb 1;66(3):1526-35.
70. Meng M, Grossfeld G, Sudilovsky D, Baehner FL. Fine-needle aspiration cytology of adult perineal rhabdomyosarcoma: a case report. *Acta Cytol.* 2006 Jan-Feb;50(1):88-92.
71. Blaveri E, Simko J, Korkola J, Brewer J, Baehner FL, Mehta K, DeVries S, Koppie T, Pejavar S, Carroll P, Waldman F. Gene expression patterns identify bladder cancer subtypes and predict outcome. *Clin Cancer Res* 2005 11: 4044-4055.
72. Baehner FL, Sudilovsky D. The fine needle aspiration cytology of balloon cell melanoma: a case report and review of the literature. *Acta Cytol.* 2005;49:543-548.
73. Paik S, Shak S, Tang, Kim C, Baker J, Cronin M, Baehner FL, Walker M, Watson D, Park T, Hiller W, Fisher E, Fisher B, Wickerham L, Bryant J, Wolmark N. Development and validation of a multi-gene RT-PCR assay for predicting recurrence in node negative, ER+, Tamoxifen-treated breast cancer patients: NSABP Studies B-20 and B-14. *N Engl J Med* 2004;351:2817-26.
74. Baehner FL, Sudilovsky D. The fine needle aspiration cytology of intra-oral epithelioid hemangioma: a report of two cases and review of the literature. *Acta Cytol.* 2003 Mar-Apr;47(2):275-80.
75. Baehner FL, Balasanian R, MacGrane G and Waldman F. Donor origin of neuroendocrine carcinoma in two transplant patients determined by molecular cytogenetics, *Hum Pathol* 2000 31(11): 1425.
76. Wilkinson C, Albanese C, Jennings R, Feldstein V, Goldberg J, Baehner FL, Farrell J, Peacock W, Harrison M. Fetal neurenteric cyst causing hydrops: case report and review of the literature. *Prenat Diagn* 1999 Feb;19(2):118-121.

OTHER CREATIVE ACTIVITIES

1. Teaching Aid: Breast pathology Primer. Development of Breast Cancer Educational Video was in collaboration with industry.